Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland
BackgroundIncreasing reports of multidrug resistance (MDR) in clinical Pseudomonas aeruginosa have led to a necessity for new antimicrobials. Ceftazidime-avibactam (CZA) is indicated for use against MDR P. aeruginosa across a broad range of infection types and particularly those that are carbapenem...
Saved in:
Main Authors: | Baharak Babouee Flury, Anja Bösch, Valentin Gisler, Adrian Egli, Salome N. Seiffert, Oliver Nolte, Jacqueline Findlay |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Cellular and Infection Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2023.1098944/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Correction: Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland
by: Baharak Babouee Flury, et al.
Published: (2025-07-01) -
Multi-omics profiling of cross-resistance between ceftazidime-avibactam and meropenem identifies common and strain-specific mechanisms in Pseudomonas aeruginosa clinical isolates
by: Bartosz J. Bartmanski, et al.
Published: (2025-07-01) -
Risk factors for mortality in patients treated with ceftazidime-avibactam for ceftazidime-avibactam susceptible carbapenem-resistant Klebsiella pneumoniae bacteremia
by: Yi-Tsung Lin, et al.
Published: (2025-09-01) -
Ceftazidime/avibactam as a possible treatment option for carbapenem-resistant Enterobacterales infections
by: Ana Kaftandzieva, et al.
Published: (2025-12-01) -
Activity of aztreonam-avibactam and ceftazidime-avibactam against β-lactamase-producing enterobacterales Isolates from United States hospitals
by: Lalitagauri M Deshpande, et al.
Published: (2025-09-01)